{"nct_id":"NCT05044234","title":"A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis","status":"TERMINATED","status_verified_date":"2023-11","start_date":"2021-11-16","start_date_type":"ACTUAL","primary_completion_date":"2022-11-30","primary_completion_date_type":"ACTUAL","completion_date":"2022-11-30","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["ABBV"]}